Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Samsung Electronics | Eli Lilly and Company | Visa | |
|---|---|---|---|
| Moat rating | narrow Samsung leads three of its four principal markets — Q1 2026 DRAM revenue share 38.5% ($37.32B, TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html), Q1 2026 NAND share 31.6% ($13.51B, TrendForce, https://www.trendforce.com/presscenter/news/20260525-13058.html), and #1 in Q2 2026 smartphones at 24% (Counterpoint via Android Authority, https://www.androidauthority.com/counterpoint-research-q2-2026-smartphone-shipment-report-3686931/) — but the moat is narrow, not wide: memory economics are violently cyclical (industry DRAM revenue swung +81% QoQ on contract-price spikes per the same TrendForce release), SK hynix holds the highest HBM bit-shipment mix among the top three (same release), and foundry trails TSMC 6.5% vs ~72% share (TrendForce data via TelecomLead, https://telecomlead.com/semiconductor/global-foundry-market-hits-record-47-95-bn-in-q1-2026-as-ai-chip-demand-drives-growth-tsmc-expands-share-to-72-126247). | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | wide The FY2025 10-K prints a network comparison for calendar year 2024: Visa at $13,433B payments volume, 311B total transactions and 4,805M cards, against Mastercard's $8,014B / 204B / 3,146M and American Express's $1,750B / 12B / 147M. Footnote (1) sources the American Express, Diners Club / Discover, JCB and Mastercard data to The Nilson Report issue 1288 (June 2025); Visa's own line is Visa's own data. On that table Visa's payments volume is roughly two-thirds larger than the next network's, and the same section states 'Based on available data, Visa is one of the largest retail electronic funds transfer networks used throughout the world.' The rating is wide because the lead rests on a two-sided installed base the filing quantifies — nearly 5 billion payment credentials and more than 175 million merchant locations across more than 200 countries and territories — which an entrant would have to reassemble on both sides at once. The table is a single-year snapshot with no prior-year column, so it evidences the size of the lead, not its direction. |
| Moat type | cost scale The durable advantage is manufacturing scale and capital intensity: the top three DRAM suppliers take roughly $8.97 of every $10 of industry revenue (Samsung 38.5% + SK hynix 28.8% + Micron 22.4% in Q1 2026 per TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html), a structure sustained by multi-billion-dollar fab economics that has admitted no new large entrant in decades; Samsung is the largest-revenue producer in both DRAM and NAND (TrendForce, https://www.trendforce.com/presscenter/news/20260525-13058.html). | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | network effects Visa itself names the two sides as the source of advantage: 'We believe our fundamental value proposition of security, convenience, speed and reliability as well as the number of payment credentials and our acceptance footprint help us to succeed.' In fiscal 2025 the 10-K counts nearly 5 billion payment credentials, which it defines as issued Visa card accounts, available at more than 175 million merchant locations, with nearly 14,500 financial institutions among the clients that build payment programs on Visa products. The two bases are joined through VisaNet in what the filing calls the 'four-party' model. Neither side is worth joining without the other, so the advantage is the mutual pull of the two installed bases rather than a patent estate or a cost curve. |
| Leadership | co leader Revenue leader in DRAM (38.5%) and NAND (31.6%) in Q1 2026 (TrendForce) and #1 in Q2 2026 smartphone shipments (Counterpoint), but not the leader where AI value concentrates: SK hynix has the highest HBM bit-shipment mix among the top three DRAM suppliers (TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html) and TSMC dominates foundry with ~72% share to Samsung's 6.5% (TrendForce via TelecomLead). | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | clear leader On the 10-K's CY2024 comparison table, Visa carried 311 billion total transactions and $13,433B of payments volume against 204 billion and $8,014B for Mastercard, the largest competitor listed. American Express is next at $1,750B and 147M cards — under a seventh of Visa's payments volume and under a thirtieth of its cards — with Diners Club / Discover ($253B, 72M cards) and JCB ($319B, 167M cards) smaller still on volume. Visa's line is its own data; the competitor lines are sourced to The Nilson Report issue 1288 (June 2025) per footnote (1). |
| Pricing power | moderate Current pricing is extraordinary but cyclical, not structural: conventional DRAM contract prices rose roughly 93-98% QoQ in Q1 2026 (TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html) — shortage-driven commodity pricing that reverses in downcycles. The set-side shows the limit: Samsung's own MX (smartphone) division posted a KRW 0.7 trillion operating loss in Q2 2026 on elevated component costs (Samsung Newsroom, https://news.samsung.com/global/samsung-electronics-announces-second-quarter-2026-results). | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | strong Visa's own take is insulated from the fees regulators target: it sets default interchange rates but does not collect them — the 10-K says 'Generally, IRFs are paid by acquirers to issuers' and that 'the fees we receive from issuers and acquirers are not derived from IRFs or MDRs.' The reported margin is high but moved down in fiscal 2025: operating income of $23,994M on $40,000M of net revenue is a 60.0% operating margin, against 65.7% ($23,595M on $35,926M) in fiscal 2024. The cause is printed two lines above operating income in the same statement — the litigation provision rose from $462M to $2,562M — and the filing says litigation provisions 'do not correlate to the underlying performance of our business' and that it excludes them 'to facilitate a comparison to our past operating performance.' Adding that provision back to operating income in both years leaves 66.4% against 67.0%, so the pricing base held and the decline is a legal charge, not a fee concession. The real limits are indirect: Dodd-Frank and the EU IFR cap interchange Visa never earns, client incentives are paid back to clients and rise with payments volume, and the UK Payment Systems Regulator holds 'wide-ranging powers and authority to review our business practices, systems, rules and fees with respect to promoting competition and innovation in the UK, and ensuring payment systems take care of, and promote, the interests of service users.' |
| Summary | Samsung Electronics is the world's largest memory maker and a vertically integrated device company. In Q1 2026 it was #1 in DRAM (38.5% revenue share) and #1 in NAND (31.6%), and in Q2 2026 it retook #1 in global smartphones at 24% share. The AI-datacenter memory shortage produced record results: Q2 2026 company revenue of KRW 171.5 trillion and an all-time-high operating profit of KRW 89.5 trillion, with server memory reaching a record share of the sales mix and HBM4E samples shipped to major customers (Samsung Newsroom). The caveats that keep the moat narrow: the profit pool is a price cycle, not a structural annuity; SK hynix leads the highest-value HBM segment by bit-shipment mix; and Samsung Foundry, at 6.5% share versus TSMC's ~72%, remains a distant second in leading-edge logic despite expanding 2nm design wins. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | Visa runs the switchboard, not the bank. The FY2025 10-K is explicit that 'Visa is not a financial institution. We do not issue cards, extend credit or set rates and fees for account holders of Visa products nor do we earn revenue from or bear credit risk with respect to any of these activities.' That disclaimer is scoped to issuing and credit extension, not to risk at large — the same filing says indemnifying issuers and acquirers for one another's settlement failures 'creates settlement risk for us' because of the timing gap between a payment transaction and its settlement. What Visa earns is service, data-processing and international-transaction revenue, reduced by client incentives, for moving other people's money: 329 billion payments and cash transactions carried the Visa brand in fiscal 2025, 258 billion of them processed by Visa, an average of 901 million a day across more than 200 countries and territories on $17 trillion of total payments and cash volume. The pull between nearly 5 billion credentials and more than 175 million merchant locations is what a rival would have to buy on both sides at once. The filing is candid about what is arriving anyway: real-time payment networks have launched in at least 80 countries behind 'strong government sponsorship and regulatory initiatives' the filing names as FedNow, PIX and UPI; B2B blockchain payments including stablecoins 'can operate globally 24/7' for cross-border transactions; and Dodd-Frank and the EU IFR both cap interchange and limit network exclusivity and routing restrictions. |
| Chain position | Upstream supplier of DRAM/HBM and NAND to the AI datacenter buildout (server memory at a record share of its Q2 2026 sales mix; HBM4E samples shipped to major customers) and a contract foundry, while simultaneously a downstream device maker (Galaxy) that consumes its own components (Samsung Newsroom, https://news.samsung.com/global/samsung-electronics-announces-second-quarter-2026-results). | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Both a buyer and a seller of AI inside payments, not an AI infrastructure supplier: the 10-K claims 'early adoption and integration of artificial intelligence (AI) models in payment systems', sells 'risk detection and prevention solutions underpinned by real-time AI-driven scores' to issuers and acquirers, and opens its rails to third-party AI systems 'via on-demand APIs, our MCP server that enables AI systems to interface with our Visa Intelligent Commerce APIs, and fully managed solutions.' |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.13 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.42 at weight 0.20 · swarm neutral Editorial prior, not backtested. |